Fabre-Kramer Pharmaceuticals

Executive Summary

Fabre-Kramer Pharmaceuticals is a US-based small molecule therapeutics company with a 30-year legacy in central nervous system (CNS) disorders. Headquartered in Houston, Texas, the company focuses on addressing significant unmet medical needs in psychiatry and neurology. Despite its long history in the CNS space, Fabre-Kramer remains privately held and has not disclosed a specific pipeline. The company's sustained focus on CNS suggests a deep understanding of the therapeutic area, but the lack of publicly available clinical-stage assets limits visibility. Fabre-Kramer likely operates on a lean model, potentially leveraging partnerships or licensing to advance its programs. The company's ability to innovate in a competitive CNS landscape will be critical for its future growth.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Readout for Lead CNS Asset40% success
• Q4 2026Regulatory Submission for Orphan Designation60% success
• 2027Potential Partnership or Licensing Deal55% success